We are leading a new study to evaluate the safety and effectivenessof a new drug known as #Avutometinib (#Avmapki®) in combinationwith the drugs #abemaciclib (Verzenio®) and #fulvestrant(Faslodex®) in metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) #BreastCancer.​